A recent report by the Alliance for Patient Access (AfPA) titled “At What Price? Medication Value, Patient Care & the Inflation Reduction Act” highlights the differences between how the federal government defines medication value and how physicians do. The report discusses a recent survey by Germany’s Federal Joint Committee that focused on how U.S. physicians view medications used to treat ulcerative colitis, psoriatic arthritis, or multiple melanoma. The survey then compared the physician’s responses to the US Government’s valuation of those same drugs for similar patients. The survey found that only 10 percent of physicians agreed with the US Government’s valuations.
AfPA also reported that these discrepancies may be attributable to the US Government’s and physician’s differing value considerations. For example, physicians value factors such as unmet needs; ability of treatment to extend life long enough for the next treatment to become available; route of drug administration; frequency of administration; and indirect benefits to patient and caregiver such as improving their ability to work. Whereas, the US Government prioritizes adequacy, appropriateness, and cost-effectiveness. Read AfPA’s full report here.
Last Updated on September 21, 2023 by Aimed Alliance
